Drugs / GEM/DOX + TGFBi expanded NK cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05634369 | Nov 2022 → Dec 2026 expected | sarcoma | Nationwide Children's Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GEM/DOX + TGFBi expanded NK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05634369 ↗ |
| Route | Intravenous | “TGFβi NK cells: via IV on Day 12” NCT05634369 ↗ |